Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Busy address KBO
13 other companies have their registered office at the same address; threshold 10.
-
Not on Peppol Peppol
Not registered in the Peppol network, mandatory for VAT-liable companies since 1 January 2026.
Financials
Financial year 2026
Jay Therapeutics from Gent, company number BE0771305101, closed financial year 2026 with a result of € 70,264 after tax. For that financial year Jay Therapeutics recorded a gross margin of € -14,524 and equity of € 10,237. Compared with financial year 2025, the result moved from € -89,854 to € 70,264. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on August 24, 2026.
€ 10,237
▲ € 70,264 vs 2025
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 70,264
▲ still € 89,854 loss in 2025
Profit after tax over the fiscal year.
€ 10,237
▼ 56% vs 2025
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2026. Retained profit grew to € -2.6 million.
People and assets in 2026
≈ 1
No payroll staff. One director, so that person most likely runs the business.
Debts at end 2026
None
No bank loans on the last day of the fiscal year.
| 2023 | 2024 | 2025 | 2026 | Change 2025 → 2026 | |
|---|---|---|---|---|---|
| Gross margin | € -96,302 | € -27,154 | € -12,088 | € -14,524 | ▼ € 2,436 |
| Profit after taxes | € -773,904 | € -158,140 | € -89,854 | € 70,264 | ▲ € 160,119 |
| Equity | € 187,967 | € 29,827 | € -60,027 | € 10,237 | ▲ € 70,264 |
| Total debts | € 73,186 | € 219,656 | € 226,146 | € 0 | ▼ 100% |
| Cash | € 80,955 | € 42,145 | € 23,341 | € 10,237 | ▼ 56% |
| Retained profit | € -2,412,033 | € -2,570,173 | € -2,660,027 | € -2,589,763 | ▲ € 70,264 |
| Bank debt | € 0 | € 192,389 | € 203,933 | € 0 | ▼ 100% |
| Balance sheet total | € 261,153 | € 249,483 | € 166,119 | € 10,237 | ▼ 94% |
Key figures of Jay Therapeutics, fiscal years 2023 to 2026, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2027) expected before 17 February 2028.
What happened to Jay Therapeutics?
What happened at Jay Therapeutics in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2026: profit of € 70,264. Source: NBB ↗
- New establishment in Gent. KBO
- V-Bio Fund 2 NV became a director. NBB
- Griet Vanpoucke became a director. NBB
- Start of the company according to the CBE. KBO
In short
From € 773,904 loss in 2023 to € 70,264 profit in 2026.
Paid € 121,229 in corporate taxes since 2023.
Best year ever: 2026, with € 70,264 profit.
Management
The stake of V-Bio Fund 2, VLAAMS INSTITUUT VOOR BIOTECHNOLOGIE - FLANDERS INSTITUTE FOR BIOTECHNOLOGY comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.
Jay TherapeuticsBehind Jay Therapeutics are V-Bio Fund 2 NV and Griet Vanpoucke. The shares are held by V-Bio Fund 2 (75%) and VLAAMS INSTITUUT VOOR BIOTECHNOLOGIE - FLANDERS INSTITUTE FOR BIOTECHNOLOGY (25%).
Directors
According to the 2026 annual accounts
since 2021
Griet Vanpoucke
Director
since 2021
Shareholders
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Pieter van Reysschootlaan 2 box 104
9051 Gent
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 13 companies are registered at this address.
All companies at this address →CD-Vastgoed
€ 437,585 gross margin · 2025
V-BIO PARTNERS 1
€ -2,244 gross margin · 2025
V-BIO MANAGEMENT 1
€ 822,886 revenue · 2025
V-Bio Fund 1
€ -903,749 gross margin · 2025
V-Bio Co-Invest 1-1
€ -16,692 gross margin · 2025
+8 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0771.305.101
- VAT number
- BE 0771.305.101
- Registered office
- Pieter van Reysschootlaan 2 bus 104, 9051 Gent
- Names & denominations
- Jay Therapeutics
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 12 July 2021
- Peppol
- Not registered
- Activities · NACE
Speur- en ontwikkelingswerk op biotechnologisch gebied